In FDC-S diagnosis, FDCSP and SRGN showed both a good sensitivity, higher than CD23 and Claudin 4, and an extremely good specificity, evaluated on 214 controls including carcinomas, soft tissue tumors, melanomas, thymomas and interdigitating dendritic cell sarcomas. The gene discussed is FCER2; the disease is melanoma.